Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Monitoring and follow-up of patients

Atul Mehta  1 , Michael Beck  2 , Aleš Linhart  3 , Gere Sunder-Plassmann  4
Atul Mehta  1 , Michael Beck  2 , Gere Sunder-Plassmann  3
, editors.
In: Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 42.
Affiliations
Free Books & Documents
Review

Monitoring and follow-up of patients

Atul Mehta et al.
Free Books & Documents

Excerpt

The availability of enzyme replacement therapy for Fabry disease has had a major impact on the organization of patient care. Many countries have produced expert guidelines outlining the recommended requirements for investigation, treatment and follow-up of patients and their families. This chapter summarizes the standards of care that operate in some of the major centres that contribute patient data to the FOS – Fabry Outcome Survey – database.

PubMed Disclaimer

References

    1. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 1998;12:115–33. - PubMed
    1. Pastores GM, Thadhani R. Advances in the management of Anderson–Fabry disease: enzyme-replacement therapy. Expert Opin Biol Ther. 2002;2:325–33. - PubMed
    1. Hughes DA, Ramaswami U, Elliott P, Deegan P, Lee P, Waldek S et al. Guidelines for the diagnosis and management of Anderson–Fabry disease. www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyA...
    1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338–46. - PubMed
    1. Guidelines for eligibility to receive treatment with agalsidase through life saving drugs program. 31 July 2004. www.health.gov.au/internet/wcms/publishinng.nsf/content/health-pbs-gener...

LinkOut - more resources